Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population

Pain Clinical Trial

Official title:

Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00450905
• Other study ID #: F06001
• Status: Terminated
• Phase: Phase 3
• First received: March 21, 2007
• Last updated: October 3, 2008
• Start date: March 2007
• Est. completion date: December 2008

Study information

• Verified date: February 2008
• Source: Fralex Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This study is being performed to determine the safety and efficacy of Fralex Neuromodulation Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal pain associated with Fibromyalgia.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 200
• Est. completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11 of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of pressure

• Males and females, 18 years and older

• Able to complete assessment index forms unaided by caregiver/interpreter

• Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the Baseline Period scores recorded on the 7 days immediately prior to randomization

• Demonstration of stabilized pain scores as measured on the NRS during the Baseline Period (Days -7 to -1)

• Able to tolerate prohibition of all medications for pain, depression and sleep disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325 mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization

• Able and willing to provide a written informed consent

Exclusion Criteria:

• Unwilling or unable to sign an informed consent, or to comply with the protocol

• Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe painful disorders that might confound assessment of FMS pain

• Currently under treatment (pharmacological or cognitive therapy) for a Major Depressive Episode (MDE) or has demonstrated suicidal ideation in the past

• History or current treatment of migraine, tension or cluster headache requiring regular medication

• History or current treatment of seizure disorder

• History or current treatment of cancer with the exception of basal cell carcinoma and cervical dysplasia

• Cognitive dysfunction or personality disorder which would preclude self-directed treatment, self assessment and / or diary completion

• Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation

• Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium (e.g. plates, implants or clips). (Metal implants in parts of the body below mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize fractures are acceptable)

• Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other electrical implanted devices

• Insufficient knowledge of English to complete the self-assessment forms

• History of or current drug or alcohol abuse

• History of abuse of a previous physician relationship or the medical system

• Receiving disability insurance, applying for disability insurance, or engaged in litigation related to FMS

• Use of an investigational drug or device in a controlled study within 30 days

• Pregnancy (U.S. sites only)

• Breastfeeding or intending to breastfeed (U.S. sites only)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes
• Pain

Intervention

Device:
• PRIMA Device

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Fralex Therapeutics	McDougall Scientific Limited, PharmaNet

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.
Secondary	Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.